Aurobindo Pharma informs about press release

02 Apr 2020 Evaluate

Aurobindo Pharma has informed that in furtherance to letter dated September 6, 2018, the Company enclosed a copy of the Press Release that is being issued by the Company on mutual termination of definitive agreement entered into for acquisition of commercial operations and three manufacturing facilities in USA from Sandoz Inc., USA, a Novartis Division by our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA since approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1090.00 13.90 (1.29%)
23-Apr-2024 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1483.75
Dr. Reddys Lab 5947.30
Cipla 1347.70
Zydus Lifesciences 958.90
Lupin 1580.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.